The selective blocking of the IL-6 receptor with tocilizumab further verified the effect of IL-6/IL-6R on the levels of E-cadherin and p-ERK in all HNSCC cell lines (Figure 2A,B and Figure S2C,D). This evidence concerns the gene CDH1 and head and neck squamous cell carcinoma.